The Power of Telehealth and CGM Technology in Diabetes Management

By Danélia Botes

November 14, 2023

The Rising Challenge of Telehealth and CGM Technology in Diabetes Management

As we celebrate World Diabetes Day, we must acknowledge the growing burden of diabetes care. With 37.3 million people in the United States diagnosed with diabetes, the healthcare industry faces a tremendous issue. The number of endocrinologists, or diabetes specialists, is frighteningly low, with a patient-to-endocrinologist ratio of 1:4375. Because of this imbalance, the majority of diabetes care is now provided in primary care settings. However, resources and expertise may be restricted in these settings. Telehealth and Continuous Glucose Monitoring CGM technology in diabetes management might enhance care for these patients in a significant way.

Continuous Glucose Monitoring (CGM) Technology’s Potential

CGM technology has demonstrated promising improvements in managing both type 1 and type 2 diabetes. CGM can lower haemoglobin A1c levels, enhance time in range (TIR) of 70 to 180 mg/dL, reduce the occurrence of hypoglycemia, and improve quality of life. Despite these advantages, however, CGM adoption is not prevalent, particularly in primary care settings.

 

The VDiSC (Virtual Diabetes Specialty Clinic)

The VDiSC, or virtual endocrinology clinic, was created to bridge the gap between an increasing number of diabetes patients and a limited number of endocrinologists. It employs telemedicine to deliver comprehensive diabetic treatment, facilitate CGM integration into diabetes self-management, and provide behavioral health support. This virtual model provides patients with type 1 and type 2 diabetes with access to specialised care without the need for actual travel, making it a more practical solution for individuals who live in rural places or have mobility concerns.

The JAMA study discovered that patients reported considerable benefits, including significant decreases in HbA1c levels and improvements in TIR. The VDiSC trial demonstrated that a virtual clinic care paradigm can deliver significant clinical advantages to diabetic patients. Telehealth services can potentially increase care access for everyone, reduce health inequities in communities, and aid in implementing breakthrough technology like CGM. The COVID-19 pandemic has made these services more accessible, showing promise for the management of chronic conditions like diabetes.

Reference url

Recent Posts

Opdivo lung cancer approval
           

FDA’s Opdivo Lung Cancer Approval

🚀 The FDA has made a groundbreaking move by approving Opdivo (nivolumab) as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC). This new regimen, combining Opdivo with platinum-doublet chemotherapy, aims to enhance patient outcomes pre- and post-surgery. With promising results from recent clinical trials, it’s a significant step forward in cancer care!

Learn more about this advancement and its implications for patients.

#SyenzaNews #CancerCare #FDAApproval

Mental Healthcare for Youth
                   

Mental Healthcare for Youth: Addressing Substance Use and Chronic Conditions

🌍🧠 Today, on World Mental Health Day, let’s focus on the mental well-being of our youth. With one in seven adolescents experiencing mental disorders, it’s crucial to address the challenges they face in accessing care. Innovative solutions like telemedicine and school-based programmes offer hope.
Let’s advocate for policies that prioritise youth mental health. Together, we can create a supportive environment for young people to thrive. 🌟
#SyenzaNews #WorldMentalHealthDay #YouthMentalHealth #MentalHealthAwareness

elacestrant breast cancer therapy
         

NICE Collaborates with Menarini to Evaluate Elacestrant Breast Cancer Treatment

🔍 The conversation surrounding elacestrant for advanced breast cancer is gaining momentum! The National Institute for Health and Care Excellence (NICE) is working closely with Menarini Stemline to address critical uncertainties in evidence. As this drug aims to tackle oestrogen receptor-positive, HER2-negative breast cancers with activating ESR1 mutations, public consultation is underway until 22 October 2024.

Stay informed about potential advancements in treatment options and the importance of collaboration in healthcare.

#SyenzaNews #BreastCancer #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.